[HTML][HTML] The role of the LDL receptor in apolipoprotein B secretion

J Twisk, DL Gillian-Daniel, A Tebon… - The Journal of …, 2000 - Am Soc Clin Investig
J Twisk, DL Gillian-Daniel, A Tebon, L Wang, PHR Barrett, AD Attie
The Journal of clinical investigation, 2000Am Soc Clin Investig
Familial hypercholesterolemia is caused by mutations in the LDL receptor gene (Ldlr).
Elevated plasma LDL levels result from slower LDL catabolism and a paradoxical
lipoprotein overproduction. We explored the relationship between the presence of the LDL
receptor and lipoprotein secretion in hepatocytes from both wild-type and LDL receptor–
deficient mice. Ldlr–/–hepatocytes secreted apoB100 at a 3.5-fold higher rate than did wild-
type hepatocytes. ApoB mRNA abundance, initial apoB synthetic rate, and abundance of the …
Familial hypercholesterolemia is caused by mutations in the LDL receptor gene (Ldlr). Elevated plasma LDL levels result from slower LDL catabolism and a paradoxical lipoprotein overproduction. We explored the relationship between the presence of the LDL receptor and lipoprotein secretion in hepatocytes from both wild-type and LDL receptor–deficient mice. Ldlr–/– hepatocytes secreted apoB100 at a 3.5-fold higher rate than did wild-type hepatocytes. ApoB mRNA abundance, initial apoB synthetic rate, and abundance of the microsomal triglyceride transfer protein 97-kDa subunit did not differ between wild-type and Ldlr–/– cells. Pulse-chase analysis and multicompartmental modeling revealed that in wild-type hepatocytes, approximately 55% of newly synthesized apoB100 was degraded. However, in Ldlr–/– cells, less than 20% of apoB was degraded. In wild-type hepatocytes, approximately equal amounts of LDL receptor–dependent apoB100 degradation occured via reuptake and presecretory mechanisms. Adenovirus-mediated overexpression of the LDL receptor in Ldlr–/– cells resulted in degradation of approximately 90% of newly synthesized apoB100. These studies show that the LDL receptor alters the proportion of apoB that escapes co- or post-translational presecretory degradation and mediates the reuptake of newly secreted apoB-containing lipoprotein particles.
The Journal of Clinical Investigation